array(40) {
  [0]=>
  string(4) "9247"
  ["article_id"]=>
  string(4) "9247"
  [1]=>
  string(70) "Digital transformation in nursing ed can increase workforce resilience"
  ["article_title"]=>
  string(70) "Digital transformation in nursing ed can increase workforce resilience"
  [2]=>
  string(159) "Tech-enabled experiential learning is elevating nursing curriculums to engage more students – and produce more graduates who say they're ready to hi"
  ["short_description"]=>
  string(159) "Tech-enabled experiential learning is elevating nursing curriculums to engage more students – and produce more graduates who say they're ready to hi"
  [3]=>
  string(216) "Tech-enabled experiential learning is elevating nursing curriculums to engage more students – and produce more graduates who say they're ready to hit the ground running in a digital health environment.&#nl"
  ["description"]=>
  string(216) "Tech-enabled experiential learning is elevating nursing curriculums to engage more students – and produce more graduates who say they're ready to hit the ground running in a digital health environment.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(105) "https://www.healthcareitnews.com/news/digital-transformation-nursing-ed-can-increase-workforce-resilience"
  ["blog_url"]=>
  string(105) "https://www.healthcareitnews.com/news/digital-transformation-nursing-ed-can-increase-workforce-resilience"
  [15]=>
  string(19) "2024-01-04 23:25:29"
  ["add_date"]=>
  string(19) "2024-01-04 23:25:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9103"
  ["article_id"]=>
  string(4) "9103"
  [1]=>
  string(112) "AskBio Phase Ib Trial of AB-1005 Gene Therapy in Patients with Parkinson’s Disease Meets Primary Endpoint"
  ["article_title"]=>
  string(112) "AskBio Phase Ib Trial of AB-1005 Gene Therapy in Patients with Parkinson’s Disease Meets Primary Endpoint"
  [2]=>
  string(150) "Berlin, Germany/Research Triangle Park, North Carolina, USA, January 4, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene t"
  ["short_description"]=>
  string(150) "Berlin, Germany/Research Triangle Park, North Carolina, USA, January 4, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene t"
  [3]=>
  string(252) "Berlin, Germany/Research Triangle Park, North Carolina, USA, January 4, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today..."
  ["description"]=>
  string(252) "Berlin, Germany/Research Triangle Park, North Carolina, USA, January 4, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(135) "https://www.drugs.com/clinical_trials/askbio-phase-ib-trial-ab-1005-gene-therapy-patients-parkinson-s-meets-primary-endpoint-21255.html"
  ["blog_url"]=>
  string(135) "https://www.drugs.com/clinical_trials/askbio-phase-ib-trial-ab-1005-gene-therapy-patients-parkinson-s-meets-primary-endpoint-21255.html"
  [15]=>
  string(19) "2024-01-04 11:01:38"
  ["add_date"]=>
  string(19) "2024-01-04 11:01:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9104"
  ["article_id"]=>
  string(4) "9104"
  [1]=>
  string(203) "New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar"
  ["article_title"]=>
  string(203) "New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar"
  [2]=>
  string(150) "NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies fo"
  ["short_description"]=>
  string(150) "NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies fo"
  [3]=>
  string(247) "NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings..."
  ["description"]=>
  string(247) "NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(148) "https://www.drugs.com/clinical_trials/new-published-data-demonstrates-correlation-between-itch-cytokine-interleukin-31-reduction-pruritis-21263.html"
  ["blog_url"]=>
  string(148) "https://www.drugs.com/clinical_trials/new-published-data-demonstrates-correlation-between-itch-cytokine-interleukin-31-reduction-pruritis-21263.html"
  [15]=>
  string(19) "2024-01-04 06:01:53"
  ["add_date"]=>
  string(19) "2024-01-04 06:01:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9105"
  ["article_id"]=>
  string(4) "9105"
  [1]=>
  string(107) "Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis"
  ["article_title"]=>
  string(107) "Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis"
  [2]=>
  string(158) "PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment "
  ["short_description"]=>
  string(158) "PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment "
  [3]=>
  string(255) "PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the initiation of its..."
  ["description"]=>
  string(255) "PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the initiation of its..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(146) "https://www.drugs.com/clinical_trials/genascence-announces-initiation-phase-1b-clinical-trial-gnsc-001-gene-therapy-knee-osteoarthritis-21253.html"
  ["blog_url"]=>
  string(146) "https://www.drugs.com/clinical_trials/genascence-announces-initiation-phase-1b-clinical-trial-gnsc-001-gene-therapy-knee-osteoarthritis-21253.html"
  [15]=>
  string(19) "2024-01-04 03:01:51"
  ["add_date"]=>
  string(19) "2024-01-04 03:01:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9106"
  ["article_id"]=>
  string(4) "9106"
  [1]=>
  string(111) "First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of Spinraza"
  ["article_title"]=>
  string(111) "First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of Spinraza"
  [2]=>
  string(150) "LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and p"
  ["short_description"]=>
  string(150) "LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and p"
  [3]=>
  string(250) "LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced the first..."
  ["description"]=>
  string(250) "LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced the first..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(136) "https://www.drugs.com/clinical_trials/first-patient-implanted-pierre-ide-clinical-study-thecaflex-drx-administration-spinraza-21252.html"
  ["blog_url"]=>
  string(136) "https://www.drugs.com/clinical_trials/first-patient-implanted-pierre-ide-clinical-study-thecaflex-drx-administration-spinraza-21252.html"
  [15]=>
  string(19) "2024-01-04 03:01:40"
  ["add_date"]=>
  string(19) "2024-01-04 03:01:40"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9248"
  ["article_id"]=>
  string(4) "9248"
  [1]=>
  string(65) "Epic's MyChart slashes administrative work at Parkview Health"
  ["article_title"]=>
  string(65) "Epic's MyChart slashes administrative work at Parkview Health"
  [2]=>
  string(131) ""The more users on the platform, the stronger the platform becomes," says the health system's digital health chief.&#nl"
  ["short_description"]=>
  string(131) ""The more users on the platform, the stronger the platform becomes," says the health system's digital health chief.&#nl"
  [3]=>
  string(131) ""The more users on the platform, the stronger the platform becomes," says the health system's digital health chief.&#nl"
  ["description"]=>
  string(131) ""The more users on the platform, the stronger the platform becomes," says the health system's digital health chief.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(95) "https://www.healthcareitnews.com/news/epics-mychart-slashes-administrative-work-parkview-health"
  ["blog_url"]=>
  string(95) "https://www.healthcareitnews.com/news/epics-mychart-slashes-administrative-work-parkview-health"
  [15]=>
  string(19) "2024-01-04 02:12:58"
  ["add_date"]=>
  string(19) "2024-01-04 02:12:58"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9249"
  ["article_id"]=>
  string(4) "9249"
  [1]=>
  string(82) "CMS-based info blocking disincentives jeopardize Medicare participation, says MGMA"
  ["article_title"]=>
  string(82) "CMS-based info blocking disincentives jeopardize Medicare participation, says MGMA"
  [2]=>
  string(154) "The Medical Group Management Association says ONC's proposed rules add undue financial burden to practices and would affect the delivery of Medicare a"
  ["short_description"]=>
  string(154) "The Medical Group Management Association says ONC's proposed rules add undue financial burden to practices and would affect the delivery of Medicare a"
  [3]=>
  string(178) "The Medical Group Management Association says ONC's proposed rules add undue financial burden to practices and would affect the delivery of Medicare and value-based care.&#nl"
  ["description"]=>
  string(178) "The Medical Group Management Association says ONC's proposed rules add undue financial burden to practices and would affect the delivery of Medicare and value-based care.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(110) "https://www.healthcareitnews.com/news/cms-based-disincentives-jeopardize-info-blocking-participation-says-mgma"
  ["blog_url"]=>
  string(110) "https://www.healthcareitnews.com/news/cms-based-disincentives-jeopardize-info-blocking-participation-says-mgma"
  [15]=>
  string(19) "2024-01-03 23:40:04"
  ["add_date"]=>
  string(19) "2024-01-03 23:40:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9107"
  ["article_id"]=>
  string(4) "9107"
  [1]=>
  string(79) "Anavex Life Sciences Provides an Update on ANAVEX®2-73 Rett Syndrome Program"
  ["article_title"]=>
  string(79) "Anavex Life Sciences Provides an Update on ANAVEX®2-73 Rett Syndrome Program"
  [2]=>
  string(150) "NEW YORK – January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage bi"
  ["short_description"]=>
  string(150) "NEW YORK – January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage bi"
  [3]=>
  string(236) "NEW YORK – January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of..."
  ["description"]=>
  string(236) "NEW YORK – January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(114) "https://www.drugs.com/clinical_trials/anavex-sciences-provides-update-anavex-2-73-rett-syndrome-program-21264.html"
  ["blog_url"]=>
  string(114) "https://www.drugs.com/clinical_trials/anavex-sciences-provides-update-anavex-2-73-rett-syndrome-program-21264.html"
  [15]=>
  string(19) "2024-01-03 07:01:28"
  ["add_date"]=>
  string(19) "2024-01-03 07:01:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9108"
  ["article_id"]=>
  string(4) "9108"
  [1]=>
  string(208) "Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)"
  ["article_title"]=>
  string(208) "Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)"
  [2]=>
  string(150) "LA JOLLA, Calif. Jan. 2, 2024-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel"
  ["short_description"]=>
  string(150) "LA JOLLA, Calif. Jan. 2, 2024-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel"
  [3]=>
  string(249) "LA JOLLA, Calif. Jan. 2, 2024-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from..."
  ["description"]=>
  string(249) "LA JOLLA, Calif. Jan. 2, 2024-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(147) "https://www.drugs.com/clinical_trials/longboard-pharmaceuticals-announces-positive-topline-data-pacific-study-phase-1b-2a-clinical-trial-21251.html"
  ["blog_url"]=>
  string(147) "https://www.drugs.com/clinical_trials/longboard-pharmaceuticals-announces-positive-topline-data-pacific-study-phase-1b-2a-clinical-trial-21251.html"
  [15]=>
  string(19) "2024-01-02 11:01:33"
  ["add_date"]=>
  string(19) "2024-01-02 11:01:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9109"
  ["article_id"]=>
  string(4) "9109"
  [1]=>
  string(89) "First Patient, First Visit in Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease"
  ["article_title"]=>
  string(89) "First Patient, First Visit in Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease"
  [2]=>
  string(158) "STUART, Fla., Dec. 29, 2023. Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of u"
  ["short_description"]=>
  string(158) "STUART, Fla., Dec. 29, 2023. Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of u"
  [3]=>
  string(259) "STUART, Fla., Dec. 29, 2023. Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced..."
  ["description"]=>
  string(259) "STUART, Fla., Dec. 29, 2023. Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(119) "https://www.drugs.com/clinical_trials/first-patient-first-visit-phase-3-clinical-trial-vezocolmitide-dry-eye-21244.html"
  ["blog_url"]=>
  string(119) "https://www.drugs.com/clinical_trials/first-patient-first-visit-phase-3-clinical-trial-vezocolmitide-dry-eye-21244.html"
  [15]=>
  string(19) "2023-12-31 06:12:52"
  ["add_date"]=>
  string(19) "2023-12-31 06:12:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9250"
  ["article_id"]=>
  string(4) "9250"
  [1]=>
  string(63) "Robotics to aid early lung cancer detection at Englewood Health"
  ["article_title"]=>
  string(63) "Robotics to aid early lung cancer detection at Englewood Health"
  [2]=>
  string(150) "Robotic-assisted bronchoscopy enables doctors to perform minimally invasive biopsies in distant areas of the lungs, including small nodules in the per"
  ["short_description"]=>
  string(150) "Robotic-assisted bronchoscopy enables doctors to perform minimally invasive biopsies in distant areas of the lungs, including small nodules in the per"
  [3]=>
  string(170) "Robotic-assisted bronchoscopy enables doctors to perform minimally invasive biopsies in distant areas of the lungs, including small nodules in the peripheral regions.&#nl"
  ["description"]=>
  string(170) "Robotic-assisted bronchoscopy enables doctors to perform minimally invasive biopsies in distant areas of the lungs, including small nodules in the peripheral regions.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(95) "https://www.healthcareitnews.com/news/robotics-aid-early-lung-cancer-detection-englewood-health"
  ["blog_url"]=>
  string(95) "https://www.healthcareitnews.com/news/robotics-aid-early-lung-cancer-detection-englewood-health"
  [15]=>
  string(19) "2023-12-29 22:39:15"
  ["add_date"]=>
  string(19) "2023-12-29 22:39:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9110"
  ["article_id"]=>
  string(4) "9110"
  [1]=>
  string(105) "IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity"
  ["article_title"]=>
  string(105) "IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity"
  [2]=>
  string(150) "CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic disease"
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic disease"
  [3]=>
  string(251) "CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S...."
  ["description"]=>
  string(251) "CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S...."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(117) "https://www.drugs.com/clinical_trials/ind-application-submitted-fda-phase-1-clinical-trial-da-1726-obesity-21242.html"
  ["blog_url"]=>
  string(117) "https://www.drugs.com/clinical_trials/ind-application-submitted-fda-phase-1-clinical-trial-da-1726-obesity-21242.html"
  [15]=>
  string(19) "2023-12-29 06:12:47"
  ["add_date"]=>
  string(19) "2023-12-29 06:12:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}